Understanding Amyloidosis Causes and Risk Factors
What Is Amyloidosis and How Does It Develop Amyloidosis is a rare disease that occurs when abnormal protein deposits build up in organs and tissues throughou...
What Is Amyloidosis and How Does It Develop
Amyloidosis is a rare disease that occurs when abnormal protein deposits build up in organs and tissues throughout the body. These deposits, called amyloid, are made from misfolded proteins that clump together in ways that damage healthy tissue. Unlike normal proteins that break down and are removed from the body, amyloid proteins resist normal breakdown processes and accumulate over time.
The disease develops when the body produces abnormal proteins or when normal proteins become misshapen. These malformed proteins stick together to form fibril structures—thin, thread-like strands that deposit in various organs. The buildup can affect the heart, kidneys, liver, nervous system, and other organs, depending on which type of amyloidosis a person has. The damage occurs gradually, often over months or years, which is why people may not notice symptoms initially.
Scientists have identified more than 30 different types of amyloidosis, each involving a different protein. The two most common forms are AL amyloidosis (light chain) and AA amyloidosis (serum amyloid A). In AL amyloidosis, bone marrow cells produce abnormal antibodies that break down into light chain proteins. In AA amyloidosis, chronic inflammation from conditions like rheumatoid arthritis triggers the production of serum amyloid A protein. Other forms include hereditary amyloidosis types, where genetic mutations cause proteins to misfold, and wild-type transthyretin amyloidosis, which typically affects older men.
The progression and severity of amyloidosis vary widely between individuals. Some people experience slowly progressive disease with minimal symptoms for years, while others develop serious organ damage more rapidly. The specific organs affected and the rate of progression depend on the amyloid protein type, the amount of amyloid accumulation, and individual factors like age and overall health.
Practical Takeaway: Understanding whether amyloidosis is hereditary, acquired, or age-related helps explain why the disease develops differently in different people. This knowledge helps individuals understand their own situation and what to expect.
Primary Risk Factors That Increase Amyloidosis Likelihood
Several established risk factors increase the probability of developing amyloidosis. Age is a significant factor, particularly for wild-type transthyretin amyloidosis, which primarily affects men over age 60. The risk increases substantially with advancing age, as protein misfolding becomes more common. For hereditary amyloidosis, age of onset varies depending on the specific genetic mutation, but symptoms typically appear between ages 20 and 60.
Genetic inheritance is a major risk factor for hereditary forms of amyloidosis. Mutations in genes that code for transthyretin protein (TTR), apolipoprotein A-I, lysozyme, fibrinogen, and other proteins can be inherited in an autosomal dominant pattern. This means that inheriting just one mutated copy of the gene from either parent increases risk substantially. Families with known hereditary amyloidosis should consider genetic screening and counseling. Currently, more than 100 different TTR mutations have been identified, and new mutations continue to be discovered.
Chronic inflammatory conditions significantly increase the risk of AA amyloidosis. These conditions include rheumatoid arthritis, tuberculosis, chronic osteomyelitis (bone infections), inflammatory bowel disease, and certain cancers. The longer someone has chronic inflammation, the higher the risk of AA amyloidosis developing. Studies show that people with long-standing rheumatoid arthritis have a substantially elevated risk compared to the general population, though the exact percentage varies by study.
Plasma cell disorders, including multiple myeloma and other conditions affecting bone marrow cells, increase AL amyloidosis risk. These disorders cause bone marrow to produce abnormal antibodies or protein fragments that can misfold into amyloid. Dialysis-related amyloidosis can develop in people who have been on kidney dialysis for extended periods, typically more than 5 to 10 years, due to accumulation of beta-2 microglobulin protein.
Lifestyle and environmental factors play smaller but measurable roles. Some research suggests that smoking may increase inflammation markers associated with amyloidosis development, though direct causation has not been definitively established. Exposure to certain occupational or environmental toxins that trigger chronic inflammation may also increase risk over decades of exposure.
Practical Takeaway: Knowing your personal and family medical history is essential. People with chronic inflammatory conditions, family history of amyloidosis, or who have been on long-term dialysis should discuss screening options with their healthcare providers.
Family History and Genetic Factors in Amyloidosis
Hereditary amyloidosis accounts for approximately 10 to 15 percent of all amyloidosis cases, making family history a critical risk factor. When a person has a parent, sibling, or other close relative with amyloidosis, their risk of carrying the same genetic mutation increases significantly. The inheritance pattern for most hereditary amyloidosis types is autosomal dominant, meaning inheriting one mutated gene copy from either parent is sufficient to cause disease.
The transthyretin gene (TTR) is the most commonly affected gene, responsible for about 80 percent of hereditary amyloidosis cases. This gene provides instructions for making transthyretin protein, which helps transport vitamin A and thyroid hormones in the blood. Over 100 documented mutations in this gene can cause amyloidosis. The specific mutation in a family determines disease characteristics, age of onset, organs affected, and progression rate. Some TTR mutations cause primarily cardiac symptoms, while others predominantly affect the nervous system or other organs.
When a parent has hereditary amyloidosis caused by a TTR mutation, each child has a 50 percent chance of inheriting the same mutation. However, inheriting the mutation does not necessarily mean a person will develop symptoms at the same age or severity as their affected parent. Penetrance—the percentage of people with the mutation who develop symptoms—varies by specific mutation. Some mutations show nearly 100 percent penetrance, meaning almost everyone who inherits them eventually develops disease. Others show lower penetrance, meaning some people with the mutation never experience symptoms during their lifetime.
Genetic testing can identify disease-causing mutations in affected families. Direct DNA testing is available for people with symptoms or those with family history. If a mutation is found, relatives can pursue carrier testing to learn whether they inherited the same mutation, even if they currently have no symptoms. Genetic counseling before and after testing helps people understand results, implications for family members, and decisions about whether to pursue screening. Some family members choose to know their genetic status, while others prefer not to be tested.
Non-hereditary amyloidosis types do not run in families in predictable patterns, though some research suggests certain genetic variations may influence individual risk. AL amyloidosis and AA amyloidosis are not inherited in the classic sense, though family members of affected individuals should be aware of the disease and its symptoms.
Practical Takeaway: Families with known hereditary amyloidosis should discuss genetic testing and counseling options. Understanding whether family members carry disease-causing mutations allows for earlier medical monitoring and potential intervention before symptoms become severe.
Age-Related and Acquired Risk Factors
Age represents one of the most significant non-genetic risk factors for amyloidosis development. Wild-type transthyretin amyloidosis, previously called senile systemic amyloidosis, primarily affects men over age 60, with the average age of diagnosis around 75 years. As people age, the transthyretin protein in their bloodstream becomes less stable and more likely to misfold into amyloid structures. This form of amyloidosis is increasingly recognized as heart disease becomes better understood through advanced imaging techniques, though it remains underdiagnosed in many populations.
AL amyloidosis typically develops in middle-aged and older adults, with average age at diagnosis around 65 years. However, younger people can develop this form when bone marrow disorders produce abnormal light chain proteins earlier in life. The incidence of AL amyloidosis appears to increase with age, suggesting cumulative exposure to risk factors or age-related changes in bone marrow function that increase the likelihood of protein misfolding.
Chronic kidney disease and long-term dialysis treatment create specific risk for dialysis-related amyloidosis. People undergoing hemodialysis for kidney failure accumulate beta-2 mic
Related Guides
More guides on the way
Browse our full collection of free guides on topics that matter.
Browse All Guides →